BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26848530)

  • 1. Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer.
    Fan Y; Zhou X; Xia TS; Chen Z; Li J; Liu Q; Alolga RN; Chen Y; Lai MD; Li P; Zhu W; Qi LW
    Oncotarget; 2016 Mar; 7(9):9925-38. PubMed ID: 26848530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taurine, glutamic acid and ethylmalonic acid as important metabolites for detecting human breast cancer based on the targeted metabolomics.
    Wang X; Zhao X; Chou J; Yu J; Yang T; Liu L; Zhang F
    Cancer Biomark; 2018; 23(2):255-268. PubMed ID: 30103303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer detection using targeted plasma metabolomics.
    Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A plasma metabolomic signature discloses human breast cancer.
    Jové M; Collado R; Quiles JL; Ramírez-Tortosa MC; Sol J; Ruiz-Sanjuan M; Fernandez M; de la Torre Cabrera C; Ramírez-Tortosa C; Granados-Principal S; Sánchez-Rovira P; Pamplona R
    Oncotarget; 2017 Mar; 8(12):19522-19533. PubMed ID: 28076849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic profiling of breast cancer: Differences in central metabolism between subtypes of breast cancer cell lines.
    Willmann L; Schlimpert M; Halbach S; Erbes T; Stickeler E; Kammerer B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():95-104. PubMed ID: 26218769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic fingerprinting in breast cancer stages through
    Suman S; Sharma RK; Kumar V; Sinha N; Shukla Y
    J Pharm Biomed Anal; 2018 Oct; 160():38-45. PubMed ID: 30059813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer.
    Liang Q; Wang C; Li B
    Appl Biochem Biotechnol; 2015 Aug; 176(8):2170-84. PubMed ID: 26088916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of metabolites and metabolic pathways in breast cancer in a Korean prospective cohort: the Korean Cancer Prevention Study-II.
    Yoo HJ; Kim M; Kim M; Kang M; Jung KJ; Hwang SM; Jee SH; Lee JH
    Metabolomics; 2018 Jun; 14(6):85. PubMed ID: 30830383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism.
    Budczies J; Brockmöller SF; Müller BM; Barupal DK; Richter-Ehrenstein C; Kleine-Tebbe A; Griffin JL; Orešič M; Dietel M; Denkert C; Fiehn O
    J Proteomics; 2013 Dec; 94():279-88. PubMed ID: 24125731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomic profiling of breast tumors using ductal fluid.
    Matos Do Canto L; Marian C; Varghese RS; Ahn J; Da Cunha PA; Willey S; Sidawy M; Rone JD; Cheema AK; Luta G; Nezami Ranjbar MR; Ressom HW; Haddad BR
    Int J Oncol; 2016 Dec; 49(6):2245-2254. PubMed ID: 27748798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of LC-MS-based metabolomics method in differentiating septic survivors from non-survivors.
    Liu Z; Yin P; Amathieu R; Savarin P; Xu G
    Anal Bioanal Chem; 2016 Nov; 408(27):7641-7649. PubMed ID: 27614981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients.
    Cui M; Wang Q; Chen G
    Biomed Chromatogr; 2016 Jan; 30(1):42-7. PubMed ID: 26179699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrative approach based on GC-qMS and NMR metabolomics data as a comprehensive strategy to search potential breast cancer biomarkers.
    Silva CL; Perestrelo R; Capelinha F; Tomás H; Câmara JS
    Metabolomics; 2021 Aug; 17(8):72. PubMed ID: 34389918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A plasma metabolite panel as biomarkers for early primary breast cancer detection.
    Yuan B; Schafferer S; Tang Q; Scheffler M; Nees J; Heil J; Schott S; Golatta M; Wallwiener M; Sohn C; Koal T; Wolf B; Schneeweiß A; Burwinkel B
    Int J Cancer; 2019 Jun; 144(11):2833-2842. PubMed ID: 30426507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
    Nishiumi S; Kobayashi T; Kawana S; Unno Y; Sakai T; Okamoto K; Yamada Y; Sudo K; Yamaji T; Saito Y; Kanemitsu Y; Okita NT; Saito H; Tsugane S; Azuma T; Ojima N; Yoshida M
    Oncotarget; 2017 Mar; 8(10):17115-17126. PubMed ID: 28179577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Breast Cancer Detection Using Untargeted and Targeted Metabolomics.
    Wei Y; Jasbi P; Shi X; Turner C; Hrovat J; Liu L; Rabena Y; Porter P; Gu H
    J Proteome Res; 2021 Jun; 20(6):3124-3133. PubMed ID: 34033488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.